Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Umeclidinium Bromide to FF/VI in COPD
NCT02119286Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of umeclidinium in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Oct 2013; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02119286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119286.